At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Not Yet Opened 07-16 16:00:00 EDT
1.89
-0.04
-2.07%
盘后1.89
+0.000.00%
17:21 EDT
High2.01Low1.86Vol38.63K
Open1.97D1 Closing1.93Amplitude7.77%
Mkt Cap7.94MTradable Cap6.87MTotal Shares4.20M
T/O74.35KT/O Rate1.06%Tradable Shares3.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon Files Form 3 for CFO Joshua Blacher
Reuters  ·  07-08
Imunon Files Form 3 for CFO Joshua Blacher
Imunon General Counsel Susan Eylward Disposes of 920 Common Shares Worth $1,729.6
Reuters  ·  07-08
Imunon General Counsel Susan Eylward Disposes of 920 Common Shares Worth $1,729.6
Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed
TIPRANKS  ·  07-01
Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed
Imunon - Jeffrey Church to Retire as Interim CFO Effective July 1, 2026 - SEC Filing
THOMSON REUTERS  ·  07-01
Imunon - Jeffrey Church to Retire as Interim CFO Effective July 1, 2026 - SEC Filing
Imunon Names Josh Blacher Interim CFO Effective July 1
Reuters  ·  07-01
Imunon Names Josh Blacher Interim CFO Effective July 1
Imunon General Counsel Susan Eylward Sells 11,800 Common Shares for $20,674.8
Reuters  ·  06-30
Imunon General Counsel Susan Eylward Sells 11,800 Common Shares for $20,674.8
Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue
MT Newswires Live  ·  06-23
Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue
Imunon announces IDMC recommendation for continuation of OVATION 3 trial
TIPRANKS  ·  06-23
Imunon announces IDMC recommendation for continuation of OVATION 3 trial
IMUNON says data monitoring committee backs continuing Phase 3 OVATION 3 ovarian cancer trial unchanged
Reuters  ·  06-23
IMUNON says data monitoring committee backs continuing Phase 3 OVATION 3 ovarian cancer trial unchanged
Imunon Announces Data Monitoring Committee Recommends Continuation of Phase 3 Ovation 3 Study Without Modification
THOMSON REUTERS  ·  06-23
Imunon Announces Data Monitoring Committee Recommends Continuation of Phase 3 Ovation 3 Study Without Modification
Imunon - Ovation 3 Trial on Track to Enroll 80 Patients by End of Q1 2027
THOMSON REUTERS  ·  06-23
Imunon - Ovation 3 Trial on Track to Enroll 80 Patients by End of Q1 2027
IMUNON CEO Stacy Lindborg to present at Life Sciences Investor Forum webcast
Reuters  ·  06-23
IMUNON CEO Stacy Lindborg to present at Life Sciences Investor Forum webcast
Imunon shareholders approve 1 million-share increase to 2018 stock incentive plan limit
Reuters  ·  06-17
Imunon shareholders approve 1 million-share increase to 2018 stock incentive plan limit
Imunon - Enters Securities Purchase Agreement With Streeterville Capital for $10 Mln Financing - SEC Filing
THOMSON REUTERS  ·  06-04
Imunon - Enters Securities Purchase Agreement With Streeterville Capital for $10 Mln Financing - SEC Filing
Imunon secures USD 10 million structured financing with preferred stock, promissory notes
Reuters  ·  06-04
Imunon secures USD 10 million structured financing with preferred stock, promissory notes
Imunon Announces up to $10 Million Cash Financing
THOMSON REUTERS  ·  06-04
Imunon Announces up to $10 Million Cash Financing
Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)
TIPRANKS  ·  05-13
Analysts Are Bullish on Top Healthcare Stocks: Ovid Therapeutics (OVID), Imunon (IMNN)
Imunon Q1 net loss widens as R&D spending rises
Reuters  ·  05-12
Imunon Q1 net loss widens as R&D spending rises
Imunon Q1 FY26 net loss widens to $4.3 million; cash drops to $4.8 million
Reuters  ·  05-12
Imunon Q1 FY26 net loss widens to $4.3 million; cash drops to $4.8 million
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate
Benzinga  ·  05-12
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--